Co-Host: Alexander Kutikov, MD, FACS

At the conclusion of these activities, participants will be able to:

1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC.

2. Identify best practices for risk assessment and patient selection for adjuvant RCC therapy.

3. Differentiate the roles of urologist and medical oncologist in the care of patients with RCC.

CME Available: auau.auanet.org/node/26087

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma